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patients. METHODS: The scale, which was translated into English from Turkish, 
again translated back into English by two independent translators, was applied to 32 
MSDs patiets for pre-test. Non working questions applied to a target group were re-
tested and then the scale was applied to the bulk of subjects (N  82). Cronbach’s 
Alfa was used to assess reliability and factor analysis to assess dimensionality. The 
EuroQol-5D was used for concurrent validity. RESULTS: Among the patients were 
15.9% ankylosing spondylitis, 6.1% rheumatoid arthritis, 24.4% osteoarthritis, 
12.2% osteoporosis, 13.4% radiculitis, 9.8% ﬁbromyalgia, 2.4% stroke, 15.9% rheu-
matic disease. The internal consistency coefﬁcient (Cronbach’s alpha) of SFS was 0.68. 
Factor analysis of the scale revealed that it was composed of three factors with Eigen-
values  1, accounting for 90.8% of the total variance. All items of the Turkish SFS 
had a factor load ranging from 0.40 to 0.77 There was a strong relationship between 
Social Functioning Scale and EuroQoL 5D. CONCLUSIONS: The Social Functioning 
Scale has good validity and reliability for Turkish MSDs patient.
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OBJECTIVES: Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are inﬂamma-
tory arthritis with signiﬁcant impact on patients’ health related quality of life (HRQL). 
The main goal of this study is to analyse the HRQL measures in these conditions. 
METHODS: Two cross sectional questionnaire surveys of consecutive patients with 
PsA (2008) and with RA (2004) were conducted in the same rheumatology outpatient 
centres in Hungary. Patients ﬁlled in the generic EQ-5D and the disease speciﬁc Health 
Assessment Questionnaire (HAQ), Psoriatic Arthritis Quality of Life Questionnaire 
(PsAQoL) / Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL). Assessing 
construct validity, patients were grouped by disease severity based on the yearly 
number of admissions to hospital, being on disability pension, use of devices and resort 
to help from others for everyday activities. The magnitude of difference between 
groups, the effect size was calculated as the standardized mean difference. Convergent 
validity was investigated by calculating the Spearman’s correlation between clinical 
scale variables and HRQL instruments. RESULTS: A total of 183 AP and 255 RA 
patients were enrolled. HRQL instruments’ scores were closer to the worse end of 
scales in case of severe PsA and RA, the highest effect size of each HRQL instrument 
was detected at use of home care. Strong correlations (rho  0.5) were observed 
between the EQ-5D, the PsAQoL / RAQoL, the HAQ disability score, the patient pain 
and global VAS. Disease duration of PsA and RA correlated weakly (rho  0.29) with 
all the HRQL instruments. CONCLUSIONS: Our results conﬁrm the good ability of 
EQ-5D, HAQ, PsAQoL/RAQoL to describe health state in PsA and RA. Our study is 
the ﬁrst to establish the correlation of HRQL instruments in PsA.
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OBJECTIVES: CZP 200 or 400 mg Q2W  methotrexate (MTX) signiﬁcantly 
improved HRQoL in patients with active RA over 1 year. Here we evaluated HRQoL 
in RA patients following long-term CZPMTX treatment. METHODS: Patients who 
completed 52 weeks treatment in RAPID 1 (completers) were eligible to enter an 
open-label (OL) study with CZP 400 mg Q2W  MTX. HRQoL was assessed using 
the SF-36 Survey that includes 8 domains (physical functioning [PF], role physical 
[RP], bodily pain [BP], general health [GH], vitality [VT], social functioning [SF], role 
emotional [RE] and mental health [MH]) grouped into summary scores: Physical (PCS) 
and Mental (MCS). MCIDs are 2.5 points for PCS/MCS and 5 for domain scores. 
Mean changes from baseline in HRQoL were analysed in completers at Week 100; 
domain scores were compared with US population norms (age/gender matched). 
RESULTS: CZP completers reported rapid and marked improvements in HRQoL at 
Weeks 12 (1st assessment) and 52 that were sustained to 100 weeks. Completers 
originally receiving CZP 200mg  MTX had mean PCS and MCS improvements of 
7.2 and 8.8 points, respectively, at Week 12, 9.1 and 8.2 points at Week 52, and 10.1 
and 7.7 points at Week 100; improvements were similar in patients originally receiving 
CZP 400 mg  MTX. Improvements in RE, GH and MH were sustained following 
long-term OL treatment, and met or exceeded MCID in PF, RP, BP and VT, which 
had the largest decrements at baseline. After 100 weeks of CZPMTX, BP, VT, SF 
and MH scores approached or met normative values. CONCLUSIONS: CZPMTX 
treatment results in rapid and clinically meaningful improvements in PCS, MCS and 
all SF-36 domains that were sustained over 2 years. BP, VT, SF and MH approached 
or met age/gender matched US population norms. Comparable beneﬁts were reported 
in RA patients enrolled in both CZP treatment arms.
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OBJECTIVES: Utility, one single value of quality of life ranged from 0 to 1, is known 
to differ between countries and available data in French population are sparse. This 
study reports on the effect of different fractures sites on self-reported EQ-5D in the 
post-menopausal osteoporosis population. METHODS: This cross-sectional study 
was carried out in general population by self completion questionnaire. Eligible 
women were those diagnosed for osteoporosis and aged 50 years and over. Utility was 
assessed using the index and VAS (range: 0–100) scores of the EQ-5D. For each group, 
the mean EQ-5D scores are reported. Univariate analysis on EQ5D index score permit-
ted to select covariables. As commonly used in health status studies, multivariate linear 
model including previous variables was performed in order to identify factors that 
most affected respondents’ EQ-5D scores. RESULTS: Questionnaires from a total of 
637 osteoporotic women were analysed. Among them, 228 already suffered a fracture. 
Last osteoporotic fracture sites reported were hip (N  22), vertebrae (N  45), wrist 
(N  80), rib (N  65), and others (N  16). Fractured women were older (mean age: 
70.3 o 8.1 vs 67.0 o 7.1 years; p  0.0001), had higher BMI values (p  0.0167) than 
others. When adjusted for age, the index and VAS scores of the EQ-5D were both 
signiﬁcantly different (p  0.01) between fractured (0.72 o 0.25; 68.3 o 16.46) and 
non fractured women (0.77 o 0.20; 72.3 o 14.82). Moreover, patient’s utility signiﬁ-
cantly decreased for hip and vertebral fractures with 0.114 and 0.102, respectively 
(p  0.01). However, loss of utility for patient with other fractures was not signiﬁcant 
(0.017; p  0.41). CONCLUSIONS: Both hip and vertebral fractures showed durable 
loss of utility, whereas other osteoporotic sites do not. Used for cost-utility analyses, 
mean QALYs of fractures for French osteoporotic population could be also 
calculated.
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OBJECTIVES: The impact of rheumatoid arthritis (RA) on patients’ work ability is 
well established. However, there is growing recognition of the impact on patients’ 
ability to perform household duties and social activities. This evaluates the impact of 
certolizumab pegol (CZP) plus methotrexate (MTX) on productivity within and 
outside the home in patients with active RA. METHODS: In RAPID1 and 2, produc-
tivity was assessed 4-weekly from baseline using the novel validated Work Productivity 
Survey (WPS-RA) that measures productivity limitations due to RA on work outside 
the home, household work and social activities. Mean changes from baseline in missed 
days of household work, days with reduced household productivity, missed days of 
family/social/leisure activities, self-reported work absenteeism and presenteeism (work 
days with productivity reduced by q50%) and RA impact on productivity a 0–10 scale 
(10  complete interference) were compared between treatment arms using non-para-
metric bootstrap-t methodology. RESULTS: A total 982 and 619 patients were ran-
domized into RAPID1, and 2, respectively. Baseline employment rates were 41.6% 
and 39.8%, respectively. The other patients included homemakers, retirees, those 
unable to work due to RA, and those unemployed for other reasons. Within each trial, 
treatment groups were comparable at baseline for productivity within and outside the 
home. In both trials, improvements in productivity within and outside the home were 
observed in the CZP arms as early as Week 4, and maintained until study end 
(RAPID1: 12 months, RAPID2: 6 months). In RAPID1, patients on CZP 200 mgMTX 
reported signiﬁcant decreases at Week 24 in days missed of household work (mean 
change 4.67 vs 1.54 days/month for MTX alone) and days with reduced productiv-
ity (mean change 5.68 vs 2.85 days/month for MTX alone). Similar improvements 
were reported with CZP 400 mgMTX and in RAPID2. Improvements in work pro-
ductivity and daily activities were reported. CONCLUSIONS: CZP improves produc-
tivity within and outside the home in RA patients.
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OBJECTIVES: To investigate the work related aspects of the burden of RA for 
patients. METHODS: A cross-sectional survey was conducted among working age 
RA patients (20 to 65 years old), members of one of the RA patients’ associations in 
France. The questionnaire was self-administered and used three validated instruments, 
the Health Assessment Questionnaire (HAQ), the EuroQoL-5 Dimension (EQ-5D) 
and the Working Productivity and Activity Impairment Questionnaire-RA (WPAI-
RA). RESULTS: A total of 3494 questionnaires were mailed and 1,189 (34.0%) could 
